Registration: 144A/Reg S; Comments: 07/07/2020 Avantor Funding Inc (AVTR) approx USD2bn (up from USD1.452bn) 144A/Reg S sr notes 2-part. B3/B-/BB (positive/positive/stable). Via GS/Citi/Barc/JPM/BofA joint books, PNC, HSBC, Evercore (US$ tranche only), Jefferies as co-managers. No reg rights. Settles 07/17 (T+8).
- USD1.550bn (up from USD1bn) due 07/15/28 (8y). NC3 (MWC T+50bp), then at 102.313, 101.156, 100. Equity claw: 3y 40% at 104.625. 144A CUSIP: 05352TAA7. IPT: 5.00%-5.25%. Px talk: 4.75%-5.00%. Launched: $1.55bn at 4.625%. Priced: 4.625% at 100. +407bp vs 2.875% 08/15/28.
- EUR400m due 07/15/28 (8y). NC3 (MWC B+50bp), then at 101.938, 100.969, 100. Equity claw: 3y 40% at 103.875. IPT 4.00%-4.25%. Px talk: 4% area. Launched: EUR400m at 3.875%. Priced: 3.875% at 100. +443bp vs DBR 0.25% 08/15/28.
Did investor call at 2pm UKT, 9am NYT 07/07. Books closed at 12pm NYT/5pm UKT 07/07. Reconfirms were due at 1pm NYT/ 6pm UKT 07/07. UOP: along with $140m cash on hand to redeem all (up from USD1.452bn portion) of its USD2bn 9% sr notes due 10/01/25 (MWC T+50bp), USD550m upsize UOP: to redeem all its 9% sr sr notes. Also increasing and extending its revolver from $250m due Nov 2022 to $515m due July 2025. Biz: a global provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, HQ: Radnor, PA.;
Registration: 144A/Reg S; Comments: 07/07/2020 Avantor Funding Inc (AVTR) approx USD2bn (up from USD1.452bn) 144A/Reg S sr notes 2-part. B3/B-/BB (positive/positive/stable). Via GS/Citi/Barc/JPM/BofA joint books, PNC, HSBC, Evercore (US$ tranche only), Jefferies as co-managers. No reg rights. Settles 07/17 (T+8).
- USD1.550bn (up from USD1bn) due 07/15/28 (8y). NC3 (MWC T+50bp), then at 102.313, 101.156, 100. Equity claw: 3y 40% at 104.625. 144A CUSIP: 05352TAA7. IPT: 5.00%-5.25%. Px talk: 4.75%-5.00%. Launched: $1.55bn at 4.625%. Priced: 4.625% at 100. +407bp vs 2.875% 08/15/28.
- EUR400m due 07/15/28 (8y). NC3 (MWC B+50bp), then at 101.938, 100.969, 100. Equity claw: 3y 40% at 103.875. IPT 4.00%-4.25%. Px talk: 4% area. Launched: EUR400m at 3.875%. Priced: 3.875% at 100. +443bp vs DBR 0.25% 08/15/28.
Did investor call at 2pm UKT, 9am NYT 07/07. Books closed at 12pm NYT/5pm UKT 07/07. Reconfirms were due at 1pm NYT/ 6pm UKT 07/07. UOP: along with $140m cash on hand to redeem all (up from USD1.452bn portion) of its USD2bn 9% sr notes due 10/01/25 (MWC T+50bp), USD550m upsize UOP: to redeem all its 9% sr sr notes. Also increasing and extending its revolver from $250m due Nov 2022 to $515m due July 2025. Biz: a global provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries, HQ: Radnor, PA.;
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.